Epirium
Manufacturing · California, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
9171 Towne Centre Dr Ste 270, San Diego,...Website
www.epirium.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
3
1
1
1
1
About Epirium
Epirium Bio is a biopharmaceutical company focused on developing orally bioavailable small molecules to address neuromuscular diseases and inflammatory conditions. Their lead product, MF-300, is currently in a Phase 2b study for sarcopenia, with additional preclinical data supporting its efficacy in conditions like spinal muscular atrophy and idiopathic pulmonary fibrosis. Founded in 2008, the company has evolved through various stages, emphasizing innovative therapies for patients with significant unmet medical needs. Epirium Bio aims to leverage its unique mechanisms of action to restore tissue homeostasis and improve patient outcomes.Explore more
Epirium Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Epirium your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Congratulate Masked Content for being promoted to Masked Content at Epirium
Website visits: Recent activity has been detected on your website
Check out if Epirium is spiking on competitors!
Earning: See what the market has to say on Epirium recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Epirium, which may be a good buyer, showed buying intent in Masked Content Topic
Check if Epirium has recently received funding, and reach out quickly before it becomes old news!
Click to see if Epirium had a recent Job posting/layoffs
Funding: Get notified immidiatlly once Epirium has new funding data
Product Launch: Get notified when Epirium launches new products
Recommended Actions
Find VP level buyers at Epirium
Find 3 more new buyers
Compare Similar Companies to Epirium
Compare insights from companies similar to Epirium, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Epirium is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Epirium is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Epirium.
Epirium Tech Stack
A closer look at the technologies used by Epirium
See more technologies
Most Recent Scoops
Lateral Move
Executive Move
Executive Moves, Lateral Move, Board of Directors
Promotion
Executive Move
Executive Moves, Promotion
Promotion
Executive Move
Executive Moves, Promotion
Lateral Move
Executive Move
Executive Moves, Lateral Move, Board of Directors
Epirium News & Media
Epirium Bio Announces First Participants Dosed in Phase 1 Clinical Trial in Healthy Volunteers, Evaluating MF-300, a First-In-Class, Oral 15-PGDH Enzyme Inhibitor, for the Treatment of Sarcopenia
SAN DIEGO--(BUSINESS WIRE)--Epirium Bio, Inc. (Epirium), a biopharmaceutical company advancing medicines for neuromuscular and fibrotic diseases, today announced that it has initiated dosing of healthy volunteers in its Phase 1 dose-escalation clinical trial of MF-300, an investigational, first-in-class, orally administered,15-hydroxyprostaglandin dehydrogenase (15-PGDH) enzyme inhibitor in development for the treatment of sarcopenia, or age-induced muscle weakness. It is estimated that up to aEpirium Bio Announces FDA Clearance of Investigational New Drug Application for MF-300 and Appointment of Alex Casdin as New Chief Executive Officer and Russell Cox as Executive Chairman
SAN DIEGO--(BUSINESS WIRE)-- #DrugDiscovery--Epirium Bio, Inc. (Epirium), a biopharmaceutical company advancing medicines for neuromuscular and fibrotic diseases, is pleased to announce two significant milestones that mark a new chapter for the Company. The U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (IND) application for MF-300, a first-in-class orally administered, 15-hydroxyprostaglandin dehydrogenase (15-PGDH) enzyme inhibitor in development forEpirium Bio Presented Late-Breaking Preclinical Data of MF-300 (15-PGDH Enzyme Inhibitor) at the Gerontological Society of America Annual Scientific Meeting 2024
SAN DIEGO--(BUSINESS WIRE)--Epirium Bio, Inc. (Epirium), a biopharmaceutical company advancing medicines for neuromuscular and fibrotic diseases, presented preclinical data for its lead candidate, MF-300, at the Gerontological Society of America’s (GSA) annual meeting being held November 13-16, 2024, in Seattle, WA. MF-300 is a first-in-class, orally administered, 15-hydroxyprostaglandin dehydrogenase (15-PGDH) enzyme inhibitor in development for the treatment of age-induced muscle weakness, or
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Epirium
Sign Up For FreeTo access detailed company insights
Epirium Bio is a biopharmaceutical company focused on developing orally bioavailable small molecules to address neuromuscular diseases and inflammatory conditions. Their lead product, MF-300, is currently in a Phase 2b study for sarcopenia, with additional preclinical data supporting its efficacy in conditions like spinal muscular atrophy and idiop... Read More
